BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1727 related articles for article (PubMed ID: 22182943)

  • 21. Notoginsenoside Ft1 promotes angiogenesis via HIF-1α mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways.
    Shen K; Ji L; Gong C; Ma Y; Yang L; Fan Y; Hou M; Wang Z
    Biochem Pharmacol; 2012 Sep; 84(6):784-92. PubMed ID: 22771629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
    Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
    Yun SM; Jung KH; Lee H; Son MK; Seo JH; Yan HH; Park BH; Hong S; Hong SS
    Cancer Lett; 2013 May; 331(2):250-61. PubMed ID: 23340175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apoptotic and anti-angiogenic effects of Pulsatilla koreana extract on hepatocellular carcinoma.
    Hong SW; Jung KH; Lee HS; Choi MJ; Zheng HM; Son MK; Lee GY; Hong SS
    Int J Oncol; 2012 Feb; 40(2):452-60. PubMed ID: 21935571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis.
    Wang X; Bai H; Zhang X; Liu J; Cao P; Liao N; Zhang W; Wang Z; Hai C
    Carcinogenesis; 2013 Jun; 34(6):1323-30. PubMed ID: 23404993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.
    He L; Wu Y; Lin L; Wang J; Wu Y; Chen Y; Yi Z; Liu M; Pang X
    Cancer Sci; 2011 Jan; 102(1):219-25. PubMed ID: 21087351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis.
    Wu Y; Xu X; Liu M; Qin X; Wu Q; Ding H; Zhao Q
    Biochem Pharmacol; 2022 Jul; 201():115093. PubMed ID: 35580648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Chen KF; Chen HL; Tai WT; Feng WC; Hsu CH; Chen PJ; Cheng AL
    J Pharmacol Exp Ther; 2011 Apr; 337(1):155-61. PubMed ID: 21205925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5,3'-Dihydroxy-6,7,4'-trimethoxyflavanone exerts its anticancer and antiangiogenesis effects through regulation of the Akt/mTOR signaling pathway in human lung cancer cells.
    Kim KM; Heo DR; Lee J; Park JS; Baek MG; Yi JM; Kim H; Bang OS
    Chem Biol Interact; 2015 Jan; 225():32-9. PubMed ID: 25446852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reexpression of ARHI inhibits tumor growth and angiogenesis and impairs the mTOR/VEGF pathway in hepatocellular carcinoma.
    Zhao X; Li J; Zhuo J; Cai L
    Biochem Biophys Res Commun; 2010 Dec; 403(3-4):417-21. PubMed ID: 21093415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RY10-4, a novel anti-tumor compound, exhibited its anti-angiogenesis activity by down-regulation of the HIF-1α and inhibition phosphorylation of AKT and mTOR.
    Liu Z; Yuan Q; Zhang X; Xiong C; Xue P; Ruan J
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1633-40. PubMed ID: 22565593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
    Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z
    Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity.
    Bagli E; Stefaniotou M; Morbidelli L; Ziche M; Psillas K; Murphy C; Fotsis T
    Cancer Res; 2004 Nov; 64(21):7936-46. PubMed ID: 15520200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
    Zhou Q; Lui VW; Yeo W
    Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects.
    Maffucci T; Piccolo E; Cumashi A; Iezzi M; Riley AM; Saiardi A; Godage HY; Rossi C; Broggini M; Iacobelli S; Potter BV; Innocenti P; Falasca M
    Cancer Res; 2005 Sep; 65(18):8339-49. PubMed ID: 16166311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway.
    Chen C; Chang YC; Liu CL; Liu TP; Chang KJ; Guo IC
    Endocr Relat Cancer; 2007 Jun; 14(2):513-29. PubMed ID: 17639064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-κB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IκB kinase complex signaling axis in adenoid cystic carcinoma.
    Sun ZJ; Chen G; Zhang W; Hu X; Liu Y; Zhou Q; Zhu LX; Zhao YF
    Mol Pharmacol; 2011 Jan; 79(1):106-18. PubMed ID: 20959361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
    Kim MN; Lee SM; Kim JS; Hwang SG
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 87.